Explore KEYTRUDA® patient profiles
Explore efficacy and safety profile results for KEYTRUDA® after prior therapy in metastatic MSI-H or dMMR CRC.
Discover results from the KEYNOTE-177 trialExplore efficacy and safety profile results for KEYTRUDA® after prior therapy in metastatic MSI-H or dMMR CRC.
Discover results from the KEYNOTE-164 trialAE=adverse event; CEA: carcinoembryonic antigen; CPS=combined positive score; CRC= colorectal cancer; ECOG PS=Eastern Cooperative Oncology Group performance status; NCCN=National Comprehensive Cancer Network®; PD-L1=programmed death-ligand 1.
†Fictitious patient profile. May not be reflective of all patients.
References:
- 1. KEYTRUDA® Product Monograph. Merck Canada Inc. April 19, 2023.
- 2. Mayo Clinic. Microsatellite Instability, Tumor. Available at: https://www.mayocliniclabs.com/test-catalog/Overview/609364. Accessed February 14, 2022.
- 3. College of American Pathologists. POET Report: Prognostic Uses of MSI Testing. Available at: https://webapps.cap.org/apps/docs/committees/technology/microsatellite_testing.pdf. Accessed February 14, 2022.
- 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 11, 2022.
- 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 11, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
CA-OVA-00054